Research programme: anticancer therapeutics - Aminex Therapeutics

Drug Profile

Research programme: anticancer therapeutics - Aminex Therapeutics

Alternative Names: AMX 513; AMXT 1501/DFMO; AMXT-1501/difluoromethylornithine; AMXT-1501/eflornithine

Latest Information Update: 08 May 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Aminex Therapeutics
  • Class Small molecules
  • Mechanism of Action Immunostimulants; Ornithine decarboxylase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Solid tumours
  • No development reported Head and neck cancer

Most Recent Events

  • 01 Apr 2017 Pharmacodynamics data from the preclinical studies in Solid tumours presented at the 108th Annual Meeting of the American Association for Cancer Research (AACR-2017)
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Head-and-neck-cancer in USA
  • 18 Nov 2015 Aminex Therapeuctics plans a phase I/IIa trial for solid tumours in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top